WO2014062228A8 - Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament - Google Patents

Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament Download PDF

Info

Publication number
WO2014062228A8
WO2014062228A8 PCT/US2013/032502 US2013032502W WO2014062228A8 WO 2014062228 A8 WO2014062228 A8 WO 2014062228A8 US 2013032502 W US2013032502 W US 2013032502W WO 2014062228 A8 WO2014062228 A8 WO 2014062228A8
Authority
WO
WIPO (PCT)
Prior art keywords
tumor cells
nanovectors
therapeutic compositions
targeting
nanovector
Prior art date
Application number
PCT/US2013/032502
Other languages
English (en)
Other versions
WO2014062228A1 (fr
Inventor
David S. BASKIN
Daniela MARCANO
Martyn A. Sharpe
James M. Tour
Original Assignee
William Marsh Rice University
The Methodist Hospital Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by William Marsh Rice University, The Methodist Hospital Research Institute filed Critical William Marsh Rice University
Priority to US14/436,127 priority Critical patent/US20150216975A1/en
Priority to CA2912975A priority patent/CA2912975A1/fr
Priority to JP2015537686A priority patent/JP2015536319A/ja
Publication of WO2014062228A1 publication Critical patent/WO2014062228A1/fr
Publication of WO2014062228A8 publication Critical patent/WO2014062228A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Divers modes de réalisation de la présente invention concernent des compositions thérapeutiques pour le ciblage spécifique de cellules tumorales. Dans certains modes de réalisation, les compositions thérapeutiques comprennent en général : (1) une pluralité de nanovecteurs; (2) un ou plusieurs principes actifs associés aux nanovecteurs, le ou les principes actifs ayant une activité dirigée contre les cellules tumorales; (3) un ou plusieurs activateurs de principe actif associés aux nanovecteurs; et (4) un ou plusieurs agents de ciblage associés aux nanovecteurs, le ou les agents de ciblage ayant une activité de reconnaissance pour un ou plusieurs marqueurs des cellules tumorales. Des modes de réalisation supplémentaires de la présente invention concernent des procédés de ciblage de cellules tumorales chez un sujet par l'administration d'une ou plusieurs des compositions thérapeutiques susmentionnées au sujet. Des modes de réalisation supplémentaires de la présente invention concernent des procédés de formulation des compositions thérapeutiques susmentionnées pour le ciblage de cellules tumorales chez un sujet d'une manière personnalisée.
PCT/US2013/032502 2007-10-03 2013-03-15 Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament WO2014062228A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/436,127 US20150216975A1 (en) 2007-10-03 2013-03-15 Nanovector based drug delivery system for overcoming drug resistance
CA2912975A CA2912975A1 (fr) 2012-10-16 2013-03-15 Systeme d'administration de medicament a base d'un nanovecteur ameliore pour surmonter la resistance a un medicament
JP2015537686A JP2015536319A (ja) 2012-10-16 2013-03-15 薬剤耐性を克服するための改善されたナノベクターベースの薬物送達システム

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261714478P 2012-10-16 2012-10-16
US61/714,478 2012-10-16

Publications (2)

Publication Number Publication Date
WO2014062228A1 WO2014062228A1 (fr) 2014-04-24
WO2014062228A8 true WO2014062228A8 (fr) 2015-06-11

Family

ID=50488627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/032502 WO2014062228A1 (fr) 2007-10-03 2013-03-15 Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament

Country Status (3)

Country Link
JP (1) JP2015536319A (fr)
CA (1) CA2912975A1 (fr)
WO (1) WO2014062228A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2776029T3 (es) 2012-10-08 2020-07-28 St Jude Childrens Res Hospital Terapias basadas en el control de la estabilidad y función de las células T reguladoras por medio de un eje neuropilina-1:semaforina
US10278991B2 (en) 2014-05-14 2019-05-07 Targimmune Therapeutics Ag Polyethyleneimine polyethyleneglycol vectors
WO2016098562A1 (fr) * 2014-12-19 2016-06-23 グリコ栄養食品株式会社 COMPOSITION SOLUBILISANTE OU DISPERSANTE POUR SUBSTANCES PEU SOLUBLES OU INSOLUBLES COMPORTANT UN SYSTÈME π-CONJUGUÉ
CN108017623A (zh) * 2017-12-06 2018-05-11 石家庄学院 一种聚乙二醇三氮唑白杨素衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7195780B2 (en) * 2002-10-21 2007-03-27 University Of Florida Nanoparticle delivery system
TW200307563A (en) * 2002-02-14 2003-12-16 Sixty Inc C Use of BUCKYSOME or carbon nanotube for drug delivery
US20060216341A1 (en) * 2003-04-02 2006-09-28 Paul Tardi Compositions for treating drug resistance
EP1722762A2 (fr) * 2004-03-02 2006-11-22 Massachusetts Institute of Technology Systeme d'administration de medicaments par nanocellules
CN101652126B (zh) * 2006-08-08 2013-07-17 得克萨斯大学体系董事会 活性试剂的多级递送
WO2009070380A2 (fr) * 2007-10-03 2009-06-04 William Marsh Rice University Compositions de nanotubes de carbone solubles dans l'eau pour l'administration d'un médicament et applications médicales
WO2011087548A2 (fr) * 2009-10-27 2011-07-21 William Marsh Rice University Compositions thérapeutiques et méthodes d'administration ciblée de principes actifs

Also Published As

Publication number Publication date
CA2912975A1 (fr) 2014-04-24
JP2015536319A (ja) 2015-12-21
WO2014062228A1 (fr) 2014-04-24

Similar Documents

Publication Publication Date Title
WO2011133925A3 (fr) Administration cytosolique photoactivée et ciblée de médicament
SG10201806917PA (en) Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
WO2012103038A3 (fr) Compositions de nanoparticules, leurs formulations et leurs utilisations
WO2014205317A3 (fr) Peptides cycliques utilisés en tant qu'agents de ciblage de protéines
WO2013067199A3 (fr) Administration sous-cutanée de conjugués polymères d'agents thérapeutiques
MD20170009A2 (ro) Compoziţii veterinare antiparazitare orale cu conţinut de agenţi activi cu acţiune sistemică, metode şi aplicări ale acestora
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
AU2011274619A8 (en) miRNA and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated BRAF pathway
WO2015023649A3 (fr) Peptides destinés à améliorer l'administration transdermique
WO2012119065A3 (fr) Agents antifongiques et leurs utilisations
TN2014000345A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
WO2013156488A3 (fr) Agents thérapeutiques sous-cutanés optimisés
WO2011087548A3 (fr) Compositions thérapeutiques et méthodes d'administration ciblée de principes actifs
WO2012097264A3 (fr) Compositions pharmaceutiques pour administration topique de photosensibilisateurs et utilisations de celles-ci
WO2013112525A3 (fr) Évènement pdab4468.18.07.1de coton résistant aux herbicides
WO2014062228A8 (fr) Système d'administration de médicament à base d'un nanovecteur amélioré pour surmonter la résistance à un médicament
WO2012040331A3 (fr) Nanoparticules multicouches
WO2013052158A3 (fr) Nanovecteurs ciblés et leur utilisation pour le traitement de tumeurs cérébrales
MX364934B (es) Agente para prevenir y/o tratar dolor neuropático periférico causado por fármaco contra el cáncer.
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
UA111324C2 (uk) Агент для профілактики або зменшення пігментації
WO2011017306A3 (fr) Direction d'agents thérapeutiques
BR112014007177A2 (pt) agente antifúngico
PH12015500374A1 (en) Extended release compositions of an aminoalkyl nitrate
WO2014093818A3 (fr) Utilisation d'une nouvelle technique sous-cutanée sans aiguille pour administrer de la testostérone chez des hommes souffrant d'hypogonadisme

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13847700

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase in:

Ref document number: 2015537686

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14436127

Country of ref document: US

ENP Entry into the national phase in:

Ref document number: 2912975

Country of ref document: CA

122 Ep: pct application non-entry in european phase

Ref document number: 13847700

Country of ref document: EP

Kind code of ref document: A1